Overview

Double-blind, Placebo-control, Study to Evaluate the Safety and Pharmacokinetics of CT-044 HCl, in Healthy Volunteers

Status:
Active, not recruiting

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

This study will be conducted to assess safety, tolerability, and PK of CT-044 HCl in normal healthy volunteers, in a traditional sequential multiple ascending dose paradigm. The multiple-dose escalation is designed to mimic the manner in which the product (CT-044 HCl) would be used to manage ongoing pain in patients (i.e., multiple dosing).

Phase:

Phase 1

Details

Lead Sponsor:

Lotus Clinical Research, LLC

Collaborator:

CerSci Therapeutics